Poolbeg Pharma - On Track to Commence LPS Human Challenge Clinical Trial

POLB Fri, 01 Apr 2022, 07:05 BST

Jeremy Skillington, PhD, CEO of Poolbeg Pharma, discusses the latest announcement that the Company has signed a Clinical Trial Agreement with the Centre for Human Drug Research in the Netherlands for the completion of a bacterial lipopolysaccharide ('LPS') human challenge study of POLB 001, which is due to commence in June 2022. First results are expected before the end of 2022 at which point the Company aims to rapidly monetise by partnering or out-licensing the asset to pharma/biotech for further development.